turnover in patients with treatment-refractory depressive illness.
J Affect Disord 74: 185–189.
Fergusson D, Douucette S, Glass KC, Shapiro S, Healy D, Hebert P
et al (2005). Association between suicide attempts and selective
serotonin reuptake inhibitors: systematic review of randomized
controlled trials. BMJ 330: 396–399.
Foote SL, Aston-Jones G, Bloom FE (1980). Impulse activity of
locus coeruleus neurons in awake rats and monkeys is a function
of sensory stimulation and arousal. Proc Natl Acad Sci USA 77:
3033–3037.
Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2005). The relationship between antidepressant medication use and rate of suicide.
Arch Gen Psychiatry 62: 165–172.
Goodman WK, Murphy TK, Storch EA (2007). Risk of adverse
behavioral effects with pediatric use of antidepressants. Psychopharmacology 191: 87–96.
Graham AW, Aghajanian GK (1971). Effects of amphetamine on
single-cell activity in a catecholamine nucleus, the locus
coeruleus. Nature 234: 100–102.
Grant MM, Weiss JM (2001). Effects of chronic antidepressant
drug administration and electroconvulsive shock on locus
coeruleus electrophysiological activity. Biol Psychiatry 49:
117–129.
Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P
(2003). Association between antidepressant prescribing and
suicide in Australia, 1991–2000: trend analysis. BMJ 326: 1008.
Hammad TA, Laughren T, Racoosin J (2006). Suicidality in
pediatric patients treated with antidepressant drugs. Arch Gen
Psychiatry 63: 332–339.
Jick H, Kaye JA, Jick SS (2004). Antidepressants and the risk of
suicidal behaviors. JAMA 292: 338–343.
Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG,
Zussman BD et al (1989). A review of the metabolism and
pharmacokinetics of paroxetine in man. Acta Psychiatr Scand
80(Suppl 350): 60–75.
Korf J, Bunney BS, Aghajanian GK (1974). Noradrenergic neurons:
morphine inhibition of spontaneous activity. Eur J Pharmacol
25: 165–169.
Laughren TP (2006). November 16, 2006 Memorandum: overview
for December 13 meeting of psychopharmacology drugs
advisory committee. Food and Drug Administration, Center for
Drug Evaluation & Research. Available at: http://www.fda.
gov/OHRMS/DOCKETS/AC/06/briefing/2006-4272b1-01-FDA.pdf.
Accessed on 1 February 2007.
Lundmark J, Scheel Thomsen I, Fjord-Larsen T, Manniche PM,
Mengel H, Moller-Nielsen EM et al (1989). Paroxetine:
pharmacokinetic and antidepressant effect in the elderly. Acta
Psychiatr Scand 80(Suppl 350): 76–80.
Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA,
Goodwin FK et al (2006). ACNP task force report on SSRIs and
suicidal behavior in youth. Neuropsychopharmacology 31: 473–492.
McConathy J, Capello C, Jarkas N, Stowe ZN, Owens MJ (2007).
Preparation of antidepressants for use in preclinical research.
Internat J Neuropsychopharmacology 10: 759–763.
Mosholder AD, Willy M (2006). Suicidal adverse events in
pediatric randomized, controlled clinical trials of antidepressant
drugs are associated with active drug treatment: a meta-analysis.
J Child Adolesc Psychopharmacol 16: 25–32.
National Strategy for Suicide Prevention. http://mentalhealth.
samhsa.gov/suicideprevention/depression.asp. Accessed on
December 2007.
Nestler EJ, McMahon A, Sarban EL, Tallman JF, Duman RS (1990).
Chronic antidepressant administration decreases the expression
of tyrosine hydroxylase in the rat locus coeruleus. Proc Natl
Acad Sci USA 87: 7522–7526.
Newman TB (2004). Treating depression in children: a black-box
warning for antidepressants in children? N Engl J Med 351:
1595–1598.
